Home > Products > Vibrenta
Share Print This Page

Vibrenta (Insulin Glargin (rDNA))
Therapeutic Group: Bio Tech » Insulin and Its Preparations

Vibrenta User Pack: Each user pack contains 1 vial of 3 ml Insulin Glargin (rDNA), 2 sterile disposable 1 ml 100 IU syringes with needle, user manual & styrofoam for heat insulation.

Vibrenta 100 IU vial: Each ml solution contains Insulin Glargine (rDNA) INN 100 IU.

Vibrenta (Insulin glargine [rDNA] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Vibrenta is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.

Primary function of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.
Vibrenta is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Dosage & Administration
Vibrenta exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.

Vibrenta is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Vibrenta must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Vibrenta must be used in regimens with short-acting insulin. Vibrenta is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.

Injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next.

Initiation of Vibrenta therapy:
The recommended starting dose of Vibrenta in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.
The recommended starting dose of Vibrenta in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient\\\'s needs.

Converting to Vibrenta from other insulin therapies
If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Vibrenta, the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted.

- If transferring patients from once-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is the same as the dose of NPH that is being discontinued.

- If transferring patients from twice-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is 80% of the total NPH dose that is being discontinued.
Side Effects
Side effects of Insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.
Dose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision.

Administration: Insulin glargine must not be diluted or mixed with any other insulin or solution. It should not be administered subcutaneously via an insulin pump or intravenously because severe hypoglycemia can occur.

Renal or hepatic impairment: Reduction in the Insulin glargine dose may require in these cases.
Insulin glargine is contraindicated in patients with hypersensitivity to Insulin glargine or one of its excipients.
Use in Pregnancy & Lactation
Pregnancy: Pregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when Insulin glargine is administered to a nursing woman. Lactating women may require adjustments in insulin dose & diet.
Drug Interaction
A number of drugs affect glucose metabolism and may require dose adjustment.

The following substances may reduce the Insulin as well as Insulin glargine requirements:

oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics.

The following substances may increase the Insulin as well as Insulin glargine requirements:
Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol.

Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Insulin glargine overdose may result in hypoglycemia. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Severe hypoglycemia may be treated with parenteral glucose or injections of glucagon. Adjustments in drug dosage, meal patterns, or exercise may be needed.
Store at 2° C to 8° C in a refrigerator. Do not freeze. Protect from light.
Commercial Packaging
Vibrenta User Pack: Each user pack contains 1 vial of 3 ml Insulin Glargin (rDNA), 2 sterile disposable 1 ml 100 IU syringes with needle, user manual & styrofoam for heat insulation.

Vibrenta 100 IU vial: Each box contains 3 ml glass vial. Each ml solution contains Insulin Glargine (rDNA) INN 100 IU.

Products from the same therapeutic group
Bio Tech
Anti Coagulant
Enoxaparin Sodium BP
STK  Injection
Streptokinase 1 500 000 IU Injection.
Drugs for hematological disorder
Recombinant Human Erythropoietin BP
Filgrastim 30 MU
Pegylated Interferon alfa-2a pre-filled syringe 180 microgram and 135 microgram
Pegylated Filgrastim Injection
Insulin and Its Preparations
Human Insulin (rDNA) Vial and Cartridge
Insulin Glargine (rDNA) Injection

Other christian louboutin outlet collection comes in mermaid shoes cut. There are two samples of louboutin sneakers shown in the pictures. Both shoes are different indeed with stylish and creative details on certain areas such as skirt, waist and chest. To match the latest christian louboutin model, these mermaid cut wedding shoes a la princess of fairytale apply sweetheart strapless neckline cut. Thick ruffle details are applied on the first louboutin schuhe. The ruffle application is combined with pleated details on the louboutin shoes uk. Thus, in conclusion, the christian louboutin schuhe is extremely very marvelous for your modern fairytale bridal. Women always like louboutin. Sometimes, you will find louboutin damen schuhe online. But they are high quality louboutin schuhe deutschland. Best louboutin schuhe outlet for girls. The 1:1 christian louboutin are also perfect. Luxury louboutin schoenen for sale online.